Half-Life (Normalesrd) Hours
6-24 (dose dependent)/No data
Plasma Protein Binding %
60
Volume Of Distribution L/Kg
4.6
Dose For Normal Renal Function
6 mg/kg IV 2 doses or 200 mg PO q12h
Second Dose
Second Dose: 4 mg/kg IV or 200 mg PO q12h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% (IV not recommended) [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% (IV not recommended) [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No adjustment necessary (oral only), [B]
Supplement For Dialysis [Recommendation Level]: Pd
PD: No adjustment necessary (oral only), [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 100%, [B]
References
Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002; 46: 2546-53. [PMID: 12121931] / Robatel C, Rusca M, Padoin C, Marchetti O, Liaudet L, Buclin T. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. J Antimicrob Chemother. 2004; 54: 269-70. [PMID: 15175271] / Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000; 34: 1032-43. [PMID: 10981251]
Toxicity Notes
Drug is cleared by hemodialysis (clearance 121 mL/min) but not sufficient to require dose adjustment or supplementation. Vehicle (for IV form) clearance is 55 mL/min. Caution is recommended, with avoidance of IV form of drug if possible, in patients with CrCl <50 mL/min due to possible accumulation of solubilizing agent.